COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I FLVFLV REGNR2 LY-CoVLY RemdesivirRMD
Vitamin D study #36 of 71
11/12 Late treatment study
Rastogi et al., Postgraduate Medical Journal, doi:10.1136/postgradmedj-2020-139065 (Peer Reviewed)
Short term, high-dose vitamin D supplementation for COVID-19 disease: a randomised, placebo-controlled, study (SHADE study)
Source   PDF   Share   Tweet
53% reduction in PCR+ with high-dose cholecalciferol supplementation. RCT with 16 treatment patients and 24 control patients.
Relative risk of PCR+ at 2 weeks with treatment, RR 0.47, p=0.18
25(OH)D levels at day 14 were 52 ng/ml vs. 15 ng/ml in the intervention and control group.

Rastogi et al., 11/12/2020, Randomized Controlled Trial, India, South Asia, peer-reviewed, 8 authors, dosage 60,000IU days 1-7.
risk of no virological cure, 52.6% lower, RR 0.47, p = 0.02, treatment 6 of 16 (37.5%), control 19 of 24 (79.2%).

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 71 studies
Please send us corrections, updates, or comments.